Patients and families nationwide are excited by news of the FDA approval of Leqembi™ (lecanemab) as a new drug for Alzheimer’s Disease (AD). This disease modifying therapy (DMT) is a great first step forward for confronting this debilitating condition that impacts millions of Americans. The drug is designed to target beta-amyloid, a protein in the brain that is thought …
FDA approval of LEQEMBI™ (lecanemab) as a new drug for Alzheimer’s Disease (AD) is a great first step forward for making disease modifying therapies (DMT) available to patients and families in their fight against this debilitating condition that impacts millions of Americans. Importantly, this positive news marks a turning point for clinicians, payers and all stakeholders in …
Recent Comments